Signal
AstraZeneca expands KRAS dealmaking and extends actinium-225 supply pact
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2025-12-31 06:00 UTCUpdated 2025-12-31 06:00 UTC
rss
astrazenecaoncologykraslicensing_dealradioisotopesmanufacturing_supply
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
AstraZeneca appeared in two oncology-related reports: it fronted $100 million to secure rights to a clinical-stage, multitarget KRAS asset from China’s Jacobio Pharma, and it extended a supply deal with Michigan-based Niowave by 10 years to support delivery of Actinium-225...
Score total
0.81
Momentum 24h
0
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Both updates were published in the same 24-hour window
- One report centers on a $100M rights deal; the other on a decade-long supply extension
Why it matters
- Signals parallel focus on oncology pipeline assets and enabling supply inputs
- Highlights KRAS as an active area of dealmaking activity for AstraZeneca
- Shows long-horizon planning via a 10-year extension for Actinium-225 delivery
LLM analysis
Topic mix: mediumPromo risk: lowSource quality: medium
Recurring claims
- AstraZeneca fronted $100 million to secure rights to a clinical-stage, multitarget asset from Jacobio Pharma to go deeper into the KRAS space.
- AstraZeneca extended its supply deal with Niowave by 10 years to tee up delivery of Actinium-225, described as promising as a component in targeted cancer therapy.
How sources frame it
- Fierce Biotech (All): neutral
- Fierce Pharma (All): neutral
Two AstraZeneca moves in oncology—one pipeline-focused, one supply-chain-focused—landed within the same news cycle.
All evidence
All evidence
Pharma giant AstraZeneca extended its supply deal with Michigan-based medical radioisotope producer Niowave by 10 years, teeing up the delivery of Actinium-225 that has shown pr...
Fierce Pharma (All) · fiercepharma.com · 2025-12-31 06:00 UTC
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma.
Fierce Biotech (All) · fiercebiotech.com · 2025-12-31 06:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- Fierce Biotech (All) (1)
Top origin domains (this list)
- fiercepharma.com (1)
- fiercebiotech.com (1)